Clinical pharmacology of angiotensin II type 1 receptor antagonists

Paul Chan, G. Neil Thomas, Yi Jen Chen, Brian Tomlinson

研究成果: 雜誌貢獻回顧型文獻同行評審

1 引文 斯高帕斯(Scopus)

摘要

The angiotensin II type 1 receptor antagonists are the latest class of antihypertensive agents to be approved for treatment of hypertension. They have a similar efficacy in lowering blood pressure as other classes of antihypertensive agents. The blood pressure-lowering effect is potentiated when given concomitantly with low-dose thiazide diuretics. These agents are well-tolerated, with an incidence of adverse effects similar to that of placebo and significantly lower than experienced with the other class of renin-angiotensin system antagonists, the angiotensin-converting enzyme inhibitors. Dose adjustments are often not necessary in patients with renal or hepatic insufficiency or in the elderly. In summary, these agents are efficacious for blood pressure lowering with a single daily dose.

原文英語
頁(從 - 到)1-10
頁數10
期刊Acta Cardiologica Sinica
18
發行號1
出版狀態已發佈 - 2002

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

指紋 深入研究「Clinical pharmacology of angiotensin II type 1 receptor antagonists」主題。共同形成了獨特的指紋。

引用此